2 weeks Ago By ABMN Staff
Accolade, Inc. ( NASDAQ:ACCD – Get Free Report ) was the recipient of a significant growth in short interest in September. As of September 15th, there was short interest totalling 4,530,000 shares, a growth of 6.
8% from the August 31st total of 4,240,000 shares. Based on an average daily volume of 1,550,000 shares, the days-to-cover ratio is currently 2.9 days.
Analyst Ratings Changes Several brokerages recently issued reports on ACCD. Stifel Nicolaus decreased their target price on Accolade from $13.00 to $8.
00 and set a “buy” rating on the stock in a research note on Friday, June 28th. Canaccord Genuity Group lowered their target price on shares of Accolade from $16.00 to $13.
00 and set a “buy” rating on the stock in a report on Friday, June 28th. Truist Financial dropped their target price on shares of Accolade from $14.00 to $9.
00 and set a “buy” rating for the company in a research report on Friday, June 28th. Barclays reduced their price target on shares of Accolade from $11.00 to $5.
50 and set an “equal weight” rating on the stock in a report on Friday, June 28th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $13.00 price target on shares of Accolade in a research note on Monday, June 24th.
Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat, Accolade presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.65.
Get Our Latest Stock Report on ACCD Accolade Stock Down 0.3 % Institutional Investors Weigh In On Accolade A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ACCD. Allspring Global Investments Holdings LLC bought a new position in Accolade during the 1st quarter valued at about $87,000.
SG Americas Securities LLC purchased a new position in shares of Accolade during the second quarter valued at approximately $43,000. GGV Capital LLC grew its stake in shares of Accolade by 242.9% during the first quarter.
GGV Capital LLC now owns 18,063 shares of the company’s stock valued at $189,000 after buying an additional 12,795 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Accolade by 15.
3% in the first quarter. Price T Rowe Associates Inc. MD now owns 19,540 shares of the company’s stock worth $205,000 after buying an additional 2,586 shares during the period.
Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Accolade by 22.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,373 shares of the company’s stock worth $73,000 after acquiring an additional 3,789 shares during the last quarter.
84.99% of the stock is currently owned by hedge funds and other institutional investors. About Accolade ( Get Free Report ) Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States.
The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians. Featured Stories Receive News & Ratings for Accolade Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accolade and related companies with MarketBeat.com's FREE daily email newsletter .
.
